{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"20.4","value":"13"},{"groupId":"OG001","lowerLimit":"2.7","upperLimit":"10.3","value":"5"},{"groupId":"OG002","lowerLimit":"3.2","upperLimit":"8.0","value":"6.4"},{"groupId":"OG003","lowerLimit":"1.9","upperLimit":"6.2","value":"3.3"},{"groupId":"OG004","lowerLimit":"4.8","upperLimit":"10.8","value":"7.7"},{"groupId":"OG005","lowerLimit":"2.9","upperLimit":"5","value":"4.3"},{"groupId":"OG006","lowerLimit":"9.7","upperLimit":"21.1","value":"14.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"35"},{"groupId":"OG004","value":"60"},{"groupId":"OG005","value":"120"},{"groupId":"OG006","value":"33"}],"units":"Participants"}],"description":"PFS was defined as the time from registration to progression or death due to any cause. PFS was analyzed using Kaplan Meier method.\n\nProgression was defined as any one or more of the following:\n\n* 25% increase in serum M-component (absolute increase \\>= 0.5g/dl)\n* 25% increase in urine M-component (absolute increase \\>= 200mg/24hour\n* 25% increase in the difference between involved and uninvolved Free Light Chain levels (absolute increase \\>= 10mg/dl)\n* 25% increase in bone marrow plasma cell percentage (absolute increase of \\>=10%)\n* Definite development of new bone lesion or soft tissue plasmacytomas","dispersionType":"95% Confidence Interval","groups":[{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG000","title":"Relapsed Myeloma (<4 Prior Regimens): Low Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG001","title":"Lenalidomide Refractory Myeloma: Low Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG002","title":"Bortezomib/Lenalidomide Refractory/Relapsed Myeloma: Low Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG003","title":"Bortezomib/Lenalidomide Relapsed/Refractory Myeloma: High Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG004","title":"Relapsed Myeloma (< 4 Prior Regimens): High Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG005","title":"Relapsed/Refractory Myeloma: High Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG006","title":"Relapsed Amyloidosis: Low Dose"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 5 years)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}